Abstract:Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors lacking estrogen, progesterone, and HER-2 receptors. It accounts for 10-20% of breast cancers, appears in younger women, metastasizes fast, and is associated with poor prognosis and poor patient survival. There are no available tailored therapies for TNBC to date. One of the ways to treat TNBC is by targeting its metastasis feature. With-no-lysine kinase 1 (WNK1), which is known to interact with diverse signaling pathways including ion homeostasis, has been recently identified as one of 6 driver genes in a murine TNBC model. Published and preliminary data support the premise that WNK1 promotes epithelial-mesenchymal transition (EMT) and invasion in TNBC. Genetic and pharmacological inhibition of WNK1 blocks metastasis in a TNBC mouse model. Given the existence of four WNK isoforms in which kinase domains are 90% identical, developing a clinically available WNK1-specific inhibitor is an unmet need. We identified WNK1-selective inhibitors by a High Throughput Screen (HTS) of over 200,000 structurally diverse small molecules. A class of quinoline-derived compounds showed high specificity and potency for WNK1. A combination of molecular modeling, crystallography, and synthesis-based strategies were employed to improve the potency of compounds. Interestingly, the compound SC107-01 reported below 100 nM IC50 for WNK1 by in vitro assays. Also, it shows higher specificity for WNK1 over other kinases as evident by kinome-specificity profiling. We had previously crystallized the kinase domain of WNK1. The structure revealed its unique active site. Co-crystal structure of SC107-01 with WNK1 shows that the inhibitor binds to the WNKs' specific active site and forms a unique set of interactions. Further modifications to the SC107-01 are underway to improve bioavailability and efficacy. In vivo toxicology and drug pharmacokinetics will be conducted in mouse models. We anticipate that this work will lay the foundation for developing a small molecule that inhibits WNK1 to combat metastasis in TNBC. Citation Format: Ashari Rashmi Kannangara, Melanie Rodriguez, Julita Chlebowicz, Radha Akella, Melanie H. Cobb, Uttam Tambar, Elizabeth J. Goldsmith. Structure based small molecule drug design for targeting WNK1 in triple negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr LB506.

Structure-based pharmacophore modelling for ErbB4-kinase inhibition: a systematic computational approach for small molecule drug discovery for breast cancer

Structure-based pharmacophore modeling for precision inhibition of mutant ESR2 in breast cancer: A systematic computational approach

Structure-based virtual screening, pharmacokinetic prediction, molecular dynamics studies for the identification of novel EGFR inhibitors in breast cancer

Virtual Screening for Identification of Dual Inhibitors against CDK4/6 and Aromatase Enzyme

Development of Structure-Based Pharmacophore to Target the Β-Catenin-tcf Protein–protein Interaction

Combined Pharmacophore Models As Virtual Screening Protocol Against BRD4(1) Inhibitor

An investigation of binding interactions of tumor-targeted peptide conjugated polyphenols with the kinase domain of ephrin B4 and B2 receptors

Combining structure-based pharmacophore modeling and machine learning for the identification of novel BTK inhibitors

Pharmacophore Modeling, 3D QSAR, Molecular Dynamics Studies and Virtual Screening on Pyrazolopyrimidines as anti-Breast Cancer Agents

Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy

3D-QSAR and Molecular Docking Approaches for the Identification of Novel Phyto-inhibitors of the Cyclin-dependent Kinase 4

Integrated Bioinformatics, Computational and Experimental Methods to Discover Novel Raf/extracellular-signal Regulated Kinase (ERK) Dual Inhibitors Against Breast Cancer Cells.

Structure-Based Pharmacophore Modeling from Multicomplex: a Comprehensive Pharmacophore Generation of Protein Kinase CK2 and Virtual Screening Based on It for Novel Inhibitors.

Repurposing of approved drugs for targeting CDK4/6 and aromatase protein using molecular docking and molecular dynamics studies

Computational design, chemical synthesis, and biological evaluation of a novel ERK inhibitor (BL-EI001) with apoptosis-inducing mechanisms in breast cancer.

Abstract LB506: Structure based small molecule drug design for targeting WNK1 in triple negative breast cancer

Design of novel PLK4 inhibitors as TRIM37-amplified breast cancer drugs using 3D-QSAR, molecular docking, and molecular dynamics simulation methods

Exploratory drug discovery in breast cancer patients: A multimodal deep learning approach to identify novel drug candidates targeting RTK signaling

Identification of TBK1 inhibitors against breast cancer using a computational approach supported by machine learning

Evaluation of active recombinant catalytic domain of human ErbB-2 tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B.

Insight into Structure-Activity Relationship of New Compounds for Breast Cancer Treatment